ReviewFrontiers in cell and developmental biology2020
Regulation of Skeletal Muscle Atrophy in Cachexia by MicroRNAs and Long Non-coding RNAs.
Review in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Chronic Resistance Exercise Combined with Nutrient Timing Enhances Skeletal Muscle Mass and Strength While Modulating Small Extracellular Vesicle miRNA Profiles.Biomedicines · 2026Article
- Gut microbiota in cancer cachexia: a new frontier for research and therapy.Genes & nutrition · 2025Review
- Article
- Deciphering the mechanisms and effects of hyperglycemia on skeletal muscle atrophy.Metabolism open · 2024Review
- Acute Sarcopenia: Mechanisms and Management.Nutrients · 2024Review
- Article
- Characterization of Undiscovered miRNA Involved in Tumor Necrosis Factor Alpha-Induced Atrophy in Mouse Skeletal Muscle Cell Line.International journal of molecular sciences · 2024Article
- Developing a ceRNA-based lncRNA-miRNA-mRNA regulatory network to uncover roles in skeletal muscle development.Frontiers in bioinformatics · 2024Article
- Beneficial effects of buspirone in endothelin-1 induced stroke cachexia in rats.Molecular and cellular biochemistry · 2023Article
- Specific miRNAs are associated with human cancer cachexia in an organ-specific manner.Journal of cachexia, sarcopenia and muscle · 2023Article
- Roles of super enhancers and enhancer RNAs in skeletal muscle development and disease.Cell cycle (Georgetown, Tex.) · 2023Review
- Genome Editing to Abrogate Muscle Atrophy.Advances in experimental medicine and biology · 2023Review
- Acute Sarcopenia after Elective and Emergency Surgery.Aging and disease · 2022Review
- Exercise attenuates angiotensinⅡ-induced muscle atrophy by targeting PPARγ/miR-29b.Journal of sport and health science · 2022Article
- Muscle and Bone Defects in Metastatic Disease.Current osteoporosis reports · 2022Review
- miR-486 is essential for muscle function and suppresses a dystrophic transcriptome.Life science alliance · 2022Article
- Microproteins in skeletal muscle: hidden keys in muscle physiology.Journal of cachexia, sarcopenia and muscle · 2022Review
- Evolving Insights Into the Biological Function and Clinical Significance of Long Noncoding RNA in Glioblastoma.Frontiers in cell and developmental biology · 2022Review
- Downregulation of miR-29c promotes muscle wasting by modulating the activity of leukemia inhibitory factor in lung cancer cachexia.Cancer cell international · 2021Article
- LncRNAs as a new regulator of chronic musculoskeletal disorder.Cell proliferation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscle atrophy is a common complication of cachexia, characterized by progressive bodyweight loss and decreased muscle strength, and it significantly increases the risks of morbidity and mortality in the population with atrophy. Numerous complications associated with decreased muscle function can activate catabolism, reduce anabolism, and impair muscle regeneration, leading to muscle wasting. microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), types of non-coding RNAs, are important for regulation of skeletal muscle development. Few studies have specifically identified the roles of miRNAs and lncRNAs in cellular or animal models of muscular atrophy during cachexia, and the pathogenesis of skeletal muscle wasting in cachexia is not entirely understood. To develop potential approaches to improve skeletal muscle mass, strength, and function, a more comprehensive understanding of the known key pathophysiological processes leading to muscular atrophy is needed. In this review, we summarize the known miRNAs, lncRNAs, and corresponding signaling pathways involved in regulating skeletal muscle atrophy in cachexia and other diseases. A comprehensive understanding of the functions and mechanisms of miRNAs and lncRNAs during skeletal muscle wasting in cachexia and other diseases will, therefore, promote therapeutic treatments for muscle atrophy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.